A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Serlopitant (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Tigercat Pharma
- 18 Sep 2017 According to a Menlo Therapeutics Media Release, data were presented at at the 26th European Academy of Dermatology and Venereology conference.
- 08 Mar 2017 Results were presented at the 2017 Annual Meeting of the American Academy of Dermatology, according to a Menlo Therapeutics media release.
- 08 Mar 2017 Results published in a Menlo Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History